Does a GLP-1 raise your risk of thyroid cancer?

Dr. Linda's take

Almost every conversation I have about these medications eventually arrives at the same question, usually asked in a lower voice than the rest: is this going to give me cancer? That fear is not irrational, and it is not something you invented from a scary headline. It comes from a real warning, printed in a real box, at the top of a real drug label, and it uses the word tumor. But a warning is not a verdict. The honest answer lives in a narrower space than either the panic or the breezy reassurance you will find online. What follows is not a promise that these medicines are safe for you, because I cannot know that and neither can anyone writing on the internet. It is what the labels and the human research actually say, laid out plainly, so that the question you bring to a clinician is a sharper one than the one that has been keeping you up.

What is a boxed warning, and what does it actually mean?

It is a format the FDA reserves for a small set of situations, and it sits at the top of a drug's prescribing information, above the list of what that drug is approved to treat. The FDA ordinarily uses it to highlight an adverse reaction so serious in proportion to the drug's potential benefit that it is essential that it be considered in assessing the risks and benefits of using the drug. It can also be used to highlight a serious adverse reaction that can be reduced in frequency or severity by appropriate use of the drug, such as careful patient selection or monitoring.

That second purpose is the one people almost never hear about, and it changes how the box should be read. A warning in that box is a signal that a risk must be weighed and, in some cases, that it can be managed by choosing carefully who takes the drug. It is not an announcement that regulators have concluded the drug harms people.

What did the rodent studies actually show?

The four medicines most people ask about, Wegovy, Ozempic, Zepbound, and Mounjaro, each carry a boxed warning titled Risk of Thyroid C-Cell Tumors. The finding behind it is worth reading slowly. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. In mice and rats, semaglutide caused an increase in the incidence of thyroid C-cell tumors, both adenomas and carcinomas, after lifetime exposure. The pattern is the same for the other molecule in this class: in rats, tirzepatide causes a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors in a 2-year study at clinically relevant plasma exposures.

Those findings came from two-year carcinogenicity studies in which animals were dosed daily across essentially their entire lifespan. That design detail matters, because it is the context in which the word tumor entered this story.

Does that mean it does the same thing in humans?

This is the crucial distinction, and the labels themselves are unusually direct about it. It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. The nonclinical section says it even more bluntly: human relevance of thyroid C-cell tumors in rats is unknown and could not be determined by clinical studies or nonclinical studies.

Read that carefully, because it cuts in both directions. It does not say the risk has been ruled out, so anyone telling you these drugs are proven harmless on this point is going past the evidence. It also does not say the risk has been established in people, so anyone telling you these drugs cause thyroid cancer is going past the evidence in the other direction. Unknown means unknown. There is one more piece the labels include: cases of medullary thyroid carcinoma in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period, and the data in these reports are insufficient to establish or exclude a causal relationship in humans.

What does the human research say so far?

Two large studies looked directly at this question in people and did not land in the same place. In a French national nested case-control study of people with type 2 diabetes, use of a GLP-1 receptor agonist for one to three years was associated with an increased risk of all thyroid cancer and of medullary thyroid cancer. In a Scandinavian cohort study, GLP-1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of just under four years. In that cohort, 76 of 145,410 patients treated with a GLP-1 receptor agonist developed thyroid cancer, compared with 184 of 291,667 patients treated with a DPP-4 inhibitor.

Those two results do not agree with each other, and that disagreement is an honest description of where the human evidence currently stands. I am not going to resolve it for you in a blog post, and I would be suspicious of anyone who claims they can. For a wider view of what this class's safety picture covers beyond this one question, our overview of the safety profile of this medication class walks through the rest, and if your concern is specifically about your own thyroid, we go deeper in thyroid health and these medications.

Who should not take these medicines?

Here the labels stop hedging, and this is the part worth reading twice. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. That is not a caution to weigh. It is a line the labels draw.

This is exactly the kind of history that does not announce itself. Nobody feels a family history of medullary thyroid carcinoma, and plenty of people have never been told that a relative's thyroid cancer was that particular subtype. It is a question worth asking your family before you ask a clinician, because the answer is not something you can find on your own.

The labels also ask clinicians to counsel patients about the symptoms of thyroid tumors, which include a mass in the neck, difficulty swallowing, shortness of breath, and persistent hoarseness. And on the question everyone asks next, the labels are counterintuitive: routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma in patients treated with these medicines, and such monitoring may increase the risk of unnecessary procedures. In other words, more testing is not automatically more safety, which is a genuinely hard thing to sit with when you are worried.

What should you ask your clinician?

If you want a structured way into that conversation, Body Good Studio's quiz is built to organize your history and symptoms before you sit down with a clinician. And if you are weighing tolerability alongside this, our guide to side effects when you have PCOS covers the day-to-day picture.

Frequently asked questions

Does a GLP-1 cause thyroid cancer?

It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. That is the label's own language, and it is neither a confirmation nor a clearance. The rodent finding is real, the human question is genuinely open, and the two large human studies that examined it reached different conclusions.

Why is there a boxed warning if the human risk is unknown?

The FDA ordinarily uses it to highlight an adverse reaction so serious in proportion to the drug's potential benefit that it is essential that it be considered in assessing the risks and benefits of using the drug. It can also be used to highlight a serious adverse reaction that can be reduced in frequency or severity by appropriate use of the drug, such as careful patient selection or monitoring. A box can flag a risk that needs weighing and managing rather than one that has been proven.

Who is contraindicated?

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Medullary thyroid carcinoma is a specific subtype, so a family history of thyroid cancer generally is a reason to find out which kind it was, not an automatic answer either way.

Should I get my thyroid scanned before starting?

That is a decision for you and a clinician, not for an article. What the labels say is that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma in patients treated with these medicines, and such monitoring may increase the risk of unnecessary procedures. Screening decisions belong with someone who knows your full history.

Do all of these medications carry this warning?

The four medicines most people ask about, Wegovy, Ozempic, Zepbound, and Mounjaro, each carry a boxed warning titled Risk of Thyroid C-Cell Tumors. The wording differs slightly between the molecules, but the structure is the same across all four: a rodent tumor finding, an open human question, and a contraindication tied to one specific cancer subtype and one endocrine syndrome.

Is this article telling me the medication is safe for me?

No, and it cannot. This is general education about what the labels and the published research say. Whether any of this applies to your body depends on your personal and family history, which is a conversation for a licensed clinician who can actually see it.

References

1. U.S. Food and Drug Administration (2011). Guidance for Industry: Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products - Content and Format. U.S. Food and Drug Administration. https://www.fda.gov/media/71866/download (Accessed 2026-07-16).
2. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-16).
3. Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 (Accessed 2026-07-16).
4. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-16).
5. Eli Lilly and Company (2026). MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 (Accessed 2026-07-16).
6. Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, Pariente A, Faillie JL (2023). GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care, via PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/36356111/ (Accessed 2026-07-16).
7. Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbjornsdottir S, Jonasson C, Hveem K, Svanstrom H, Melbye M, Ueda P (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11004669/ (Accessed 2026-07-16).